Management of drug and food interactions with azole antifungal agents in transplant recipients

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 842-854

  Dodds Ashley, Elizabeth ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antifungals; CYP; Cytochrome P450; Transplant

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXAMETHASONE; FLUCONAZOLE; GASTROINTESTINAL AGENT; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METHYLPREDNISOLONE; POSACONAZOLE; PREDNISOLONE; PREDNISONE; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMYCIN; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; RECIPIENT; REVIEW; SEIZURE; SIDE EFFECT; TREMOR;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; DISEASE MANAGEMENT; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; MYCOSES; TRANSPLANTATION;

EID: 77955448192     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.842     Document Type: Review

References (101)

1. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 2005;14:755-67.
2. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Exp Opin Pharmacother 2007;8:1167-78.
3. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10:1-10.
4. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44.
5. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Exp Opin Pharmacother 2005;6:2231-43.
6. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-39.
7. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Exp Rev Anti Infect Ther 2004;2:485-97.
8. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
9. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68.
10. Lewis RE. Managing drug interactions in the patient with aspergillosis. Med Mycol 2006;44:349-56.
11. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003;56:45-50.
12. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001;41:1149-79.
13. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
14. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31.
15. Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003;37:420-32.
16. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35:720-9.
17. Omar G, Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997;19:436-45.
18. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
19. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55:53-81.
20. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyl-transferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132.
21. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71.
22. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005;33:139-46.
23. Singh N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 2004;77:795-800.
24. Gabardi S. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2007;27:e3-6.
25. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994;20:49-52.
26. Kuypers DR, Claes K, Evenepoel P, Vanrenterghem Y. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. Transplantation 2006;81:1750-2.
27. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003;35:2873-7.
28. Banerjee R, Leaver N, Lyster H, Banner NR. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 2001;33:1600-2.
29. Kramer MR, Merin G, Rudis E, et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc 1997;29:2657-9.
30. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005;24:2148-52.
31. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999;15:317-37.
32. Dhawan A, Tredger JM, North-Lewis PJ, Gonde CE, Mowat AP, Heaton NJ. Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. Transpl Int 1997;10:331-4.
33. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993;27:427-30.
34. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51:1014-18.
35. Sugar AM, Saunders C, Idelson BA, Bernard DB. Interaction of fluconazole and cyclosporine [letter]. Ann Intern Med 1989;110:844.
36. Torregrosa V, De la Torre M, Campistol JM, et al. Interaction of fluconazole with ciclosporin A. Nephron 1992;60:125-6.
37. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999;14:1698-703.
38. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002;34:1733-5.
39. Manez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994;57:1521-3.
40. Hairhara Y, Makuuchi M, Kawarasaki H, et al. Effect of fluconazole on blood levels of tacrolimus [abstract]. Transplant Proc 1999;31:2767.
41. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008;18:861-8.
42. Mathis AS, DiRenzo T, Friedman GS, Kaplan B, Adamson R. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001;71:1069-75.
43. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
44. Cervelli MJ. Fluconazole-sirolimus drug interaction [letter]. Transplantation 2002;74:1477-8.
45. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004;36:3226-8.
46. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
47. Trenk D, Brett W, Jahnchen E, Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet 1987;2:1335-6.
48. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-9.
49. Irani S, Fattinger K, Schmid-Mahler C, Achermann E, Speich R, Boehler A. Blood concentration curve of cyclosporine: impact of itraconazole in lung transplant recipients. Transplantation 2007;83:1130-3.
50. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998;46:271-2.
51. Ideura T, Muramatsu T, Higuchi M, Tachibana N, Hora K, Kiyosawa K. Tacrolimus/itraconazole interactions: a case report of ABO-incompatible living-related renal transplantation. Nephrol Dial Transplant 2000;15:1721-3.
52. Furlan V, Parquin F, Penaud JF, et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998;30:187-8.
53. Capone D, Gentile A, Imperatore P, Palmiero G, Basile V. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999;33:1124-5.
54. Outeda Macias M, Salvador P, Hurtado JL, Martin I. Tacrolimus- itraconazole interaction in a kidney transplant patient [letter]. Ann Pharmacother 2000;34:536.
55. Cervelli MJ, Russ GR. Itraconazole-tacrolimus drug interaction. Ther Drug Monit 2003;25:483-4.
56. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006;26:289-95.
57. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
58. Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004;53:113-14.
59. Tintillier M, Kirch L, Goffin E, Cuvelier C, Pochet JM. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20:664-5.
60. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004;36:2708-9.
61. Pai MP, Allen S. Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003;36:1089-91.
62. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998;4:157-63.
63. Kawazoe H, Takiguchi Y, Tanaka H, et al. Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. Biol Pharm Bull 2006;29:2528-31.
64. Myrand SP, Man MZ, Lin X, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84:347-61.
65. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:552-9.
66. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008;28:719-29.
67. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825-34.
68. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
69. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.
70. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effect of oral posaconazole (POS) on the pharmacokinetics (PK) of sirolimus. Presented at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
71. Schering Corporation. Noxafil (posaconazole) oral suspension package insert. Kenilworth, NJ; May 2008.
72. Pfizer Inc. Diflucan (fluconazole tablets, fluconazole injection - for intravenous infusion only, fluconazole for oral suspension) package insert. New York, NY; August 2004.
73. Janssen. Sporanox (itraconazole capsules) package insert. Titusville, NJ; June 2006.
74. Pfizer Inc. VFEND I.V. (voriconazole for Injection); VFEND Tablets (voriconazole); VFEND (voriconazole for oral suspension) package insert. New York, NY; November 2006.
75. Mahnke CB, Sutton RM, Venkataramanan R, et al. Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant 2003;7:474-8.
76. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-94.
77. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29-32.
78. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443-50.
79. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9.
80. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (gruppo italiano trapianto di midollo osseo). Anticancer Res 1996;16:2083-8.
81. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-7.
82. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
83. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transplant Infect Dis 2007;9:33-6.
84. Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998;16:33-7.
85. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998;54:159-61.
86. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993;7:317-21.
87. Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003;51:453-7.
88. Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002;23:77-81.
89. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56:56-61. (Pubitemid 37491735)
90. 2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56:51-5.
91. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-8.
92. Courtney R, Wexler D, Statkevich P, Lim J, Batra V, Laughlin M. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers [abstract]. Poster presented at the 42nd interscience conference on antimicrobial agents and chemotherapy; San Diego, CA, September 27-30, 2002.
93. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66.
94. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56:24-9.
95. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
96. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52.
97. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147-50.
98. Van de Velde V, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16:424-8.
99. Gubbins PO, McConnell SA, Gurley BJ, et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 2004;24:460-7.
100. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999;21:304-9.
101. Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998;36:306-8.